Serina Therapeutics, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Serina Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2025-03-31 was $4.92M, a 86.50% decline year-over-year.
- Serina Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2024-06-30 was $0.00.
- Serina Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2024-03-31 was $36.40M.
- Serina Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2021-12-31 was $0.00.
- Serina Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2025 was $2.63M, a 92.78% decline from fiscal 2024.
- Serina Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2024 was $36.40M, a 1.24% increase from fiscal 2023.
- Serina Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2023 was $35.96M.
- Serina Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2021 was $475.00K, a 1183.78% increase from fiscal 2020.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-12-31 | $2.63M 10-K · filed 2026-03-25 | |
| 2025-03-31 | $4.92M 10-Q · filed 2025-11-13 | |
| 2024-12-31 | $36.40M 10-K · filed 2025-03-24 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | |
| 2024-03-31 | $36.40M 10-Q · filed 2025-05-08 | |
| 2023-12-31 | $35.96M 10-K · filed 2024-03-22 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $475.00K 10-K · filed 2023-03-31 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $475.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $512.00K derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $475.00K 10-Q · filed 2022-05-13 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $37.00K 10-K · filed 2022-03-29 |
| 2020-09-30 | $37.00K 10-Q · filed 2020-11-16 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $56.00K 10-K · filed 2021-03-31 |
| 2019-09-30 | $56.00K 10-Q · filed 2020-11-16 | |
| 2018-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2020-03-31 | $5.00M 10-K/A · filed 2020-03-31 |
| 2018-06-30 | $5.00M 10-Q · filed 2019-08-14 | |
| 2017-12-31 | $32.00K 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |